Daiichi Sankyo sees new products, Ranbaxy taking sales to $12 billion level in three years
This article was originally published in Scrip
Daiichi Sankyo is aiming to boost its group operating profit by almost 90% to ¥180 billion ($1.98 billion) in the fiscal year ending March 31st, 2013, on net sales which are seen reaching ¥1,150 billion, a 20% increase over those forecast for the year to this March 31st.
You may also be interested in...
Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.